Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-NS: Dupilumab for Severe Nephrotic Syndrome in Children
NCT07091175Phase 2Recruiting
- Sponsor
- National University Hospital
- Start
- Nov 2025
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dupilumab in nephrotic syndrome (3 arms), sponsored by National University Hospital. Primary endpoint: Time to relapse up to 24 weeks. Started Nov 2025; status: recruiting.
02
Drugs
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT07091175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07091175.